Should You Buy Viatris Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Viatris Inc. (VTRS) carries a solid Quality of Company rating of 6.0/10. Trading at $16.65, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 5 of 6 CirclFi valuation models project upside for Viatris Inc. (VTRS) at $16.65 — the model consensus leans bullish, with a Quality Score of 6.0/10 and Value-Trap risk of 29/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Viatris Inc. (VTRS) in 2026?
What Is the Bull Case vs the Bear Case for Viatris Inc. (VTRS)?
| Bull case — $50.83 target (+205.3%) | Bear case — $14.98 target (-10.1%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $16.65 and the median fair value of $24.40 implies +46.5% upside potential. | According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $14.98 (-10.1%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $50.83 (+205.3%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +215.3% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: therapeutic area leadership could provide meaningful support for Viatris Inc.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | Industry headwind: drug pricing legislation represents a meaningful risk for Viatris Inc. and its Drug Manufacturers - Specialty & Generic peers. |
How Does VTRS Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: OGI · AQST · AAWH · TLRY · INIS · PRGO · GELS · UTHR · IRWD · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like VTRS on Quality?
Closest companies to VTRS’s Quality of Company score of 6.0/10, across all industries.
- VALN — Valneva SE (QOC 6.0) · analysis
- IE — Ivanhoe Electric Inc. (QOC 6.0) · analysis
- OESX — Orion Energy Systems, Inc. (QOC 6.0) · analysis
- UXIN — Uxin Limited (QOC 6.0) · analysis
- AIDX — 20/20 Biolabs, Inc. (QOC 6.0) · analysis
- MOGU — MOGU Inc. (QOC 6.0) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does VTRS Appear In?
So Is Viatris Inc. (VTRS) Worth Buying in 2026?
Viatris Inc. at $16.65 presents what our engine identifies as a high-conviction opportunity: 5 of 6 models see upside, quality stands at 6.0/10, and the median fair value of $24.40 implies +46.5% return potential. Investors should verify this thesis against their own risk parameters and time horizon.
These are quantitative model outputs, not investment recommendations. Viatris Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About VTRS Stock?
Should I buy VTRS stock right now?
Based on CirclFi's multi-model analysis, 5 of 6 models see upside for VTRS at $16.65. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 6.0/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Viatris Inc.?
Key risks include: limited model coverage (6/13 active), reducing analytical confidence; wide model disagreement (239% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does VTRS compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, VTRS holds a Quality Score of 6.0/10. Comparable companies include OGI (QOC 6.1), AQST (QOC 6.0), AAWH (QOC 6.1). The relative ranking helps investors identify whether VTRS offers better fundamental quality than alternatives in the same sector.
Is VTRS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. VTRS's Quality Score of 6.0/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy VTRS at?
CirclFi does not provide target buy prices or price alerts. However, our 6 active models produce fair value estimates ranging from $14.98 to $50.83. At $16.65, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for VTRS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad